Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04748185 · ClinicalTrials.gov registry record
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 358
- Enrollment target
NCT04748185: Completed study, sponsored by Mayo Clinic.
NCT04748185 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 358 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04748185 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 358 participants
- Enrollment target
Study Summary
D1. Primary Objective: 1\. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies D2. Secondary Objectives: 1. Assess the safety of FDA approved COVID-19 vaccination in patients with hematologic malignancies 2. Analyze the kinetics of immunogenic response over time after receipt of the COVID-19 vaccination 3. Compare the immunogenicity of different COVID-19 vaccinations that will be approved by the FDA 4. Analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all participants and correlate with response to vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2022-07-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04748185
The ClinicalTrials.gov registry entry for NCT04748185 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04748185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04748185 about?
NCT04748185 is a clinical study titled "Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies". D1. Primary Objective: 1\. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies D2. Secondary Objectives: 1. Assess the safety of FDA approved COVID-19 vaccination in patients with hematologic malignancies 2. Analyze the kinetics of immunogen...
What is the current status of trial NCT04748185?
This trial is currently completed. The enrollment target is 358 participants. The study started on 2021-01-28. Estimated completion is 2022-07-13.
Who is sponsoring clinical trial NCT04748185?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.